Drug-drug Interaction Clinical Trial
Official title:
An Experiment to Evaluate the Drug-drug Interaction of Formula Edaravone and Formula 2-Aminoethanesulfonic Acid in Compound Edaravone Injection
Verified date | March 2021 |
Source | Nanjing Yoko Biomedical Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An experiment to evaluate the drug-drug interaction of formula edaravone and formula 2-aminoethanesulfonic acid in compound edaravone injection.
Status | Completed |
Enrollment | 24 |
Est. completion date | May 31, 2019 |
Est. primary completion date | May 31, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Age: 18-65 years old (including upper and lower limits); 2. Weight =50 kg, body mass index (BMI) between 18-28 kg / m2 (including upper and lower limits); 3. Understand and sign the informed consent voluntarily, and volunteer to participate in this research. Exclusion Criteria: 1. A history of diseases of the heart, liver, lung, kidney, digestive tract, blood, or neuropsychiatric system judged by the investigator as clinically significant; 2. A comprehensive physical examination, neurological examination, laboratory examination, ECG examination, or cognitive assessment indicates that the subject has an abnormality that the researcher has determined to be clinically significant; 3. Have taken any drug within two weeks before the study administration, and the researcher believes that this situation may affect the evaluation results of this study; 4. There is a history of food or drug allergy or allergies that the researcher judges to be clinically significant; 5. Those with positive results of serological examination (HBsAg, anti-HCV, anti-HIV, TP-Ab); 6. A history of alcohol or drug abuse that the investigator believes may affect the evaluation results of this study within one year before the study administration; 7. Cannot quit smoking or drinking during the study period or the carbon monoxide breath test> 7 ppm during the screening period CO breath test, so if the subject's CO breath is> 7ppm, but the urine cotinine test is negative, it means that the CO breath test result may be false positive, the subject can be enrolled; 8. As a subject who has participated in any drug clinical trial within 3 months before the first administration of the study; 9. Those who donated blood or blood products =400 mL or 2 units within three months of the study; 10. Do not agree to avoid the use of tobacco, alcohol or caffeinated beverages, or vigorous exercise, or other factors that affect drug absorption, distribution, metabolism, excretion, etc. during the 24 hours before and during the test; 11. Pregnant or lactating women, or those who tested positive for serum HCG before the test administration, or those who were unable or unwilling to take researcher-approved contraception during the study according to the researcher's instructions; 12. Subjects with poor compliance or unable to comply with the relevant provisions of the research protocol due to personal reasons, the investigator judges that the subjects are not suitable to participate in this clinical study. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tiantan Hospital, Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Nanjing Yoko Biomedical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax of edaravone with and without coIntravenous with 2-Aminoethanesulfonic Acid | 24 hours | ||
Primary | AUC0-t of edaravone with and without coIntravenous with 2-Aminoethanesulfonic Acid | 24 hours | ||
Primary | AUC0-8 of edaravone with and without coIntravenous with 2-Aminoethanesulfonic Acid | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05692570 -
A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04328766 -
Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03990129 -
Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03985969 -
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
|
Phase 1 | |
Completed |
NCT03302845 -
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02887443 -
A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate
|
Phase 1 | |
Completed |
NCT01361217 -
The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
|
N/A | |
Completed |
NCT06066060 -
A DDI Study of JMKX000623 and Metformin Hydrochloride
|
Phase 1 | |
Completed |
NCT03723395 -
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
|
Phase 1 | |
Recruiting |
NCT05789173 -
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
|
Early Phase 1 | |
Completed |
NCT04598542 -
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05044962 -
Kuwa Free! - Live Free!
|
N/A | |
Completed |
NCT04487145 -
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
|
Phase 4 | |
Completed |
NCT05108051 -
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
|
Phase 1 | |
Active, not recruiting |
NCT04669678 -
Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa
|
Phase 4 | |
Completed |
NCT01991327 -
Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
|
Phase 1 | |
Completed |
NCT05492318 -
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
|
Phase 1 | |
Completed |
NCT01309854 -
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05339672 -
Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
|
||
Completed |
NCT05306379 -
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
|
Phase 1 |